Baltimore, MD
Stem Cell Therapy clinics in Baltimore
Baltimore supports a regenerative medicine market shaped by both private clinics and regional academic medicine. Local referral networks run through Johns Hopkins Hospital, University of Maryland Medical Center, and MedStar, and stem cell practice in the area spans Mount Vernon, Fells Point, and the Inner Harbor. Patient demand splits across three buckets: orthopedic injections for active adults and aging athletes, neurological and autoimmune protocols marketed to longevity-focused patients, and IV-based allogeneic products offered by private wellness clinics. The FDA classifies most stem cell injections for orthopedic, neurological, or longevity use as investigational biologics under 21 CFR Part 1271, meaning they require either a Biologics License or an active Investigational New Drug authorization. Autologous bone marrow and adipose products may qualify as Section 361 when minimally manipulated and used for homologous function. Maryland regulates physician practice through the Maryland Board of Physicians. There is no state-specific stem cell statute, so federal 21 CFR Part 1271 rules apply. Johns Hopkins and NIH campus activity drive academic trial density. The 6 Baltimore clinics listed below have been reviewed against our vetting criteria, including federal NPI lookup, OIG exclusion screening, and Maryland Board of Physicians licensure checks.
Whole Body Healthcare
- Ozone Therapy
- IV Therapy
- Arthritis Treatment
- Chelation Therapy
- Migraine Treatment
Regulatory context
A note on Maryland's stem cell therapy rules.
Maryland cellular therapy is governed by 21 CFR Part 1271. Section 361 covers minimally manipulated HCT/Ps used for homologous use without premarket approval. Section 351 covers products that are more than minimally manipulated, used non-homologously, or combined with another article, and these require an IND for clinical use or a BLA for marketing. Most stem cell, stromal vascular fraction, and exosome therapies marketed in Maryland for orthopedic, neurologic, and longevity indications are Section 351 biologics that lack FDA approval. Maryland is FDA's home state, and the agency operates extensive review and inspection capacity within state lines.
-
Maryland Medical Practice Act, Health Occupations Article Title 14
Establishes physician licensure and discipline through the Maryland Board of Physicians. -
Maryland Pharmacy Act, Health Occupations Article Title 12
Regulates compounding pharmacies aligned with federal 503A and 503B standards. -
Maryland Consumer Protection Act, Commercial Law Article Title 13
Empowers the Attorney General to pursue deceptive marketing claims against providers making unsupported clinical claims.
Maryland's proximity to FDA headquarters in Silver Spring places state clinics under close federal observation. The FDA has corresponded with Maryland providers offering cellular therapies. The Maryland Board of Physicians has disciplined physicians for unprofessional conduct including misleading regenerative medicine advertising. The Maryland Attorney General's Consumer Protection Division can pursue deceptive marketing under the Maryland Consumer Protection Act. NIH and academic medical centers in the Baltimore-DC corridor conduct compliant IND-based cellular research, which contrasts with smaller direct-to-patient clinics that may be operating without appropriate authorization.